Mr. Waldron currently serves as Chief Financial Officer of BioAtla Inc since 2014. BioAtla achieved a successful IPO in December 2020. Mr. Waldron has extensive experience in the financing and executive operations of biotechnology companies. He has served as the Chief Financial Officer of three publicly traded companies, successfully raising capital for all three and executing the merger of one of them. Prior to his work in the industry, Mr. Waldron served as a senior health care banker, executing strategically significant transactions and pioneering financial strategies for clients that included Genzyme and Genentech, and initiated the sector practice at Cowen & Company, a leading healthcare investment bank. Mr. Waldron graduated with honors from Harvard Business School, and magna cum laude from Princeton University.